Drug-Induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose Metabolism

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 4, 2016, Pages 390-400

  Anyanwagu, U ^a   Idris, I ^a   Donnelly, R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATORVASTATIN; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL L TYPE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; GLUCOSE TRANSPORTER 4; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN RECEPTOR; LEPTIN; NICOTINIC ACID; POTASSIUM; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

BODY MASS; BODY WEIGHT DISORDER; CHRONIC DISEASE; DRUG INDUCED DISEASE; EVIDENCE BASED MEDICINE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HUMAN; HYDROPHILICITY; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOPHILICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; WEIGHT GAIN; ANIMAL; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; POLYPHARMACY; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; POLYPHARMACY; RISK ASSESSMENT; RISK FACTORS;

EID: 84960372389     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.274     Document Type: Review

References (74)

1. Freeman, D.J., et al,. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103, 357-362 (2001).
2. Shepherd, J., et al,. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360, 1623-1630 (2002).
3. Culver, A.L., et al,. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch. Intern. Med. 172, 144-152 (2012).
4. Waters, D.D., et al,. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J. Am. Coll. Cardiol. 57, 1535-1545 (2011).
5. Sattar, N., et al,. Statins and risk of incident diabetes: A collaborative meta-Analysis of randomised statin trials. Lancet 375, 735-742 (2010).
6. U.S. Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. FDA Drug Safety Communication. < http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm > (2012).
7. Gissi-HF Investigators et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 372, 1231-1239 (2008).
8. Kjekshus, J., et al,. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 357, 2248-2261 (2007).
9. Navarese, E.P., et al,. Meta-Analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am. J. Cardiol. 111, 1123-1130 (2013).
10. Naci, H., Brugts, J., &, Ades, T., Comparative tolerability and harms of individual statins: A study-level network meta-Analysis of 246 955 participants from 135 randomized, controlled trials. Circ. Cardiovasc. Qual. Outcomes 6, 390-399 (2013).
11. Dormuth, C.R, et al,. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ 348, g3244 (2014).
12. Preiss, D., et al,. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-Analysis. JAMA 305, 2556-2564 (2011).
13. Study of the Effectiveness of Additional Reductions in Cholesterol Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: A double-blind randomised trial. Lancet 376, 1658-1669 (2010).
14. Carter, A.A., Gomes, T., Camacho, X., Juurlink, D.N., Shah, B.R., &, Mamdani, M.M., Risk of incident diabetes among patients treated with statins: population based study. BMJ 346, f2610 (2013).
15. Wang, K.L., et al,. Statins, risk of diabetes, and implications on outcomes in the general population. J. Am. Coll. Cardiol. 60, 1231-1238 (2012).
16. Zaharan, N.L., Williams, D., &, Bennett, K., Statins and risk of treated incident diabetes in a primary care population. Br. J. Clin. Pharmacol. 75, 1118-1124 (2013).
17. Izzo, R., et al,. Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk. Nutr. Metab. Cardiovasc. Dis. 23, 1101-1106 (2013).
18. Ko, D.T., Wijeysundera, H.C., Jackevicius, C.A., Yousef, A., Wang, J., &, Tu, J.V., Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins. Circ. Cardiovasc. Qual. Outcomes 6, 315-322 (2013).
19. Danaei, G., García Rodríguez, L.A., Fernandez Cantero, O., &, Hernán, M.A., Statins and risk of diabetes: An analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care 36, 1236-1240 (2013).
20. Cederberg, H., Stančáková, A., Yaluri, N., Modi, S., Kuusisto, J., &, Laakso, M., Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: A 6 year follow-up study of the METSIM cohort. Diabetologia 58, 1109-1117 (2015).
21. Chen, C.W., Chen, T.C., Huang, K.Y., Chou, P., Chen, P.F., &, Lee, C.C., Differential impact of statin on new-onset diabetes in different age groups: A population-based case-control study in women from an Asian country. PLoS ONE 8, e71817 (2013).
22. Wang, K.L., et al,. Risk of new-onset diabetes mellitus versus reduction in cardiovascular events with statin therapy. Am. J. Cardiol. 113, 631-636 (2014).
23. Liew, S.M., et al,. Statins use is associated with poorer glycaemic control in a cohort of hypertensive patients with diabetes and without diabetes. Diabetol. Metab. Syndr. 6, 53 (2014).
24. Kryzhanovski, V., Gumprecht, J., Zhu, B., Yu, C.Y., Hounslow, N., &, Sponseller, C.A., Atorvastatin but not pitavastatin significantly increases fasting plasma glucose in patients with type 2 diabetes and combined dyslipidemia. J. Am. Coll. Cardiol. 57, E575 (2011).
25. Simsek, S., Schalkwijk, C.G., &, Wolffenbuttel, B.H., Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes-The CORALL study. Diabet. Med. 29, 628-631 (2012).
26. Brault, M., Ray, J., Gomez, Y.H., Mantzoros, C.S., &, Daskalopoulou, S.S., Statin treatment and new-onset diabetes: A review of proposed mechanisms. Metabolism 63, 735-745 (2014).
27. Nakata, M., Nagasaka, S., Kusaka, I., Matsuoka, H., Ishibashi, S., &, Yada, T., Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 49, 1881-1892 (2006).
28. Baker, W.L., Talati, R., White, C.M., &, Coleman, C.I., Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-Analysis. Diabetes Res. Clin. Pract. 87, 98-107 (2010).
29. Henriksbo, B.D., et al,. Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes 63, 3742-3747 (2014).
30. Suazo, J., &, Rigotti, A., Risk of type 2 diabetes mellitus associated with statin therapy: evidence and possible mechanisms [in Spanish]. Rev. Med. Chil. 142, 222-228 (2014).
31. Takaguri, A., Satoh, K., Itagaki, M., Tokumitsu, Y., &, Ichihara, K., Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. J. Pharmacol. Sci. 107, 80-89 (2008).
32. Ridker, P.M., et al,. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
33. Koh, K.K., Quon, M.J., Han, S.H., Lee, Y., Kim, S.J., &, Shin, E.K., Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J. Am. Coll. Cardiol. 55, 1209-1216 (2010).
34. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
35. Alderman, M.H., New onset diabetes during antihypertensive therapy. Am. J. Hypertens. 21, 493-499 (2008).
36. Ong, K.L., Barter, P.J., &, Waters, D.D., Cardiovascular drugs that increase the risk of new-onset diabetes. Am. Heart J. 167, 421-428 (2014).
37. Salvetti, A., &, Ghiadoni, L., Thiazide diuretics in the treatment of hypertension: An update. J. Am. Soc. Nephrol. 17 (4 Suppl 2), S25-S29 (2006).
38. Ellison, D.H., &, Loffing, J., Thiazide effects and adverse effects: insights from molecular genetics. Hypertension 54, 196-202 (2009).
39. Cooper-DeHoff, R.M., et al,. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension 55, 61-68 (2010).
40. Verdecchia, P., et al,. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43, 963-969 (2004).
41. Jong, G.P., et al,. Antihypertensive drugs and new-onset diabetes: A retrospective longitudinal cohort study. Cardiovasc. Ther. 27, 159-163 (2009).
42. Huang, C.Y., et al,. A retrospective longitudinal cohort study of antihypertensive drug use and new-onset diabetes in Taiwanese patients. Biomed. Res. Int. 2013, 287696 (2013).
43. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288, 2998-3007 (2002).
44. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 265, 3255-3264 (1991).
45. Elliott, W.J., &, Meyer, P.M., Incident diabetes in clinical trials of antihypertensive drugs: A network meta-Analysis. Lancet 369, 201-207 (2007).
46. Duarte, J.D., &, Cooper-DeHoff, R.M., Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev. Cardiovasc. Ther. 8, 793-802 (2010).
47. Zillich, A.J., Garg, J., Basu, S., Bakris, G.L., &, Carter, B.L., Thiazide diuretics, potassium, and the development of diabetes: A quantitative review. Hypertension 48, 219-224 (2006).
48. Stears, A.J., et al,. A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertension 59, 934-942 (2012).
49. Vardeny, O., et al,. Opposing effects of β blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. Am. J. Cardiol. 107, 1705-1709 (2011).
50. Lee, P., Kengne, A.P., Greenfield, J.R., Day, R.O., Chalmers, J., &, Ho, KK,. Metabolic sequelae of β-blocker therapy: weighing in on the obesity epidemic? Int. J. Obes. (Lond). 35, 1395-1403 (2011).
51. DREAM Trial Investigators et al. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 355, 1551-1562 (2006).
52. De Hert, M., et al,. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in heathcare. World Psychiatry 10, 52-77 (2011).
53. Gillespie, E.L., White, C.M., Kardas, M., Lindberg, M., &, Coleman, C.I., The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 28, 2261-2266 (2005).
54. Sazonov, V., Maccubbin, D., Sisk, C.M., &, Canner, P.L., Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. Int. J. Clin. Pract. 67, 297-302 (2013).
55. Shams, T.A., &, Müller, D.J., Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers reviewed. Curr. Psychiatry Rep. 16, 473 (2014).
56. Armitage J, on behalf of the HPS2-YHRIVE Collaborative Group. HPS2-THRIVE: randomised placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Presented at the American College of Cardiology Annual Scientific Sessions, San Francisco, CA, 9 March 2013.
57. De Hert, M., Detraux, J., van Winkel, R., Yu, W., &, Correll, C.U., Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 8, 114-126 (2011).
58. Grayson, B.E., Seeley, R.J., &, Sandoval, D.A., Wired on sugar: The role of the CNS in the regulation of glucose homeostasis. Nat. Rev. Neurosci. 14, 24-37 (2013).
59. Bak, M., Fransen, A., Janssen, J., van Os, J., &, Drukker, M., Almost all antipsychotics result in weight gain: A meta-Analysis. PLoS ONE 9, e94112 (2014).
60. Galling, B., &, Correll, C.U., Do antipsychotics increase diabetes risk in children and adolescents? Expert Opin. Drug Saf. 14, 219-241 (2015).
61. Gonçalves, P., Araújo, J.R., &, Martel, F., Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Eur. Neuropsychopharmacol. 25, 1-16 (2015).
62. Deng, C., Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol. Metab. Clin. North Am. 42, 545-563 (2013).
63. Mitchell, A.J., Vancampfort, D., De Herdt, A., Yu, W., &, De Hert M,. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-Analysis of first episode, untreated and treated patients. Schizophr. Bull. 39, 295-305 (2013).
64. Vancampfort, D., et al,. A meta-Analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 12, 240-250 (2013).
65. Rubin, D.M., et al,. Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths. JAMA Pediatr. 169, e150285 (2015).
66. Smith, M., Hopkins, D., Peveler, R.C., Holt, R.I., Woodward, M., &, Ismail, K., First-v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-Analysis. Br. J. Psychiatry 192, 406-411 (2008).
67. Hartling, L., Abou-Setta, A.M., Dursun, S., Mousavi, S.S., Pasichnyk, D., &, Newton, A.S., Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: A systematic review and meta-Analysis. Ann. Intern. Med. 157, 498-511 (2012).
68. Correll, C.U., Detraux, J., De Lepeleire, J., &, De Hert, M., Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 14, 119-136 (2015).
69. Samaras, K., et al,. Diabetes risk potentially underestimated in youth and children receiving antipsychotics. JAMA Psychiatry 71, 209-210 (2014).
70. Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G.R., Chisholm, D.J., &, Cooper, D.A., Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-Associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 353, 2093-2099 (1999).
71. Capeau, J., et al,. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 26, 303-314 (2012).
72. Samaras, K., Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 50, 499-505 (2009).
73. Carr, A., &, Cooper, D.A., Adverse effects of antiretroviral therapy. Lancet 356, 1423-1430 (2000).
74. Lee, G.A., Rao, M.N., &, Grunfeld, C., The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr. HIV/AIDS Rep. 2, 39-50 (2005).